Ontology highlight
ABSTRACT:
SUBMITTER: Dal Molin GZ
PROVIDER: S-EPMC6331693 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature
Future oncology (London, England) 20180814 30
Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, PARP12, PARP15 and PARP16. Study 10 and ARIEL2 evaluated the use of rucaparib as treatment in patients with recurrent high-grade ovarian carcinoma and resulting in approval of rucaparib for patients with both germline and somatic BRCA mutation. Data from the Phase III trial ARIEL3 led to approval in platinum-sensitive disease as maintenance. This article reviews t ...[more]